Cedric O’Gorman

971 total citations
31 papers, 609 citations indexed

About

Cedric O’Gorman is a scholar working on Psychiatry and Mental health, Pharmacology and Molecular Biology. According to data from OpenAlex, Cedric O’Gorman has authored 31 papers receiving a total of 609 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Psychiatry and Mental health, 8 papers in Pharmacology and 6 papers in Molecular Biology. Recurrent topics in Cedric O’Gorman's work include Schizophrenia research and treatment (13 papers), Mental Health and Psychiatry (6 papers) and Pharmacological Receptor Mechanisms and Effects (5 papers). Cedric O’Gorman is often cited by papers focused on Schizophrenia research and treatment (13 papers), Mental Health and Psychiatry (6 papers) and Pharmacological Receptor Mechanisms and Effects (5 papers). Cedric O’Gorman collaborates with scholars based in United States, United Kingdom and Canada. Cedric O’Gorman's co-authors include Christoph U. Correll, Philip D. Harvey, John M. Kane, Tenko Raykov, Martin Strassnig, Thomas L. Patterson, Dante Durand, David L. Penn, Samir Sabbag and Amy E. Pinkham and has published in prestigious journals such as Biological Psychiatry, Journal of Affective Disorders and Schizophrenia Bulletin.

In The Last Decade

Cedric O’Gorman

30 papers receiving 597 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cedric O’Gorman United States 13 450 107 84 82 79 31 609
Luke Vano United Kingdom 5 545 1.2× 96 0.9× 59 0.7× 89 1.1× 122 1.5× 10 823
Ataru Inagaki Japan 11 386 0.9× 83 0.8× 103 1.2× 73 0.9× 48 0.6× 24 636
Margarida García-García Spain 11 794 1.8× 172 1.6× 132 1.6× 95 1.2× 73 0.9× 16 1.1k
Pilar Sierra Spain 15 494 1.1× 130 1.2× 145 1.7× 115 1.4× 113 1.4× 56 783
Gabriella Rapini Italy 14 306 0.7× 231 2.2× 100 1.2× 106 1.3× 104 1.3× 19 627
Anne Emilie Stürup Denmark 8 577 1.3× 162 1.5× 64 0.8× 58 0.7× 99 1.3× 12 929
Alexander Brunnauer Germany 12 181 0.4× 80 0.7× 98 1.2× 102 1.2× 72 0.9× 44 556
Jerónimo Sáiz Ruiz Spain 12 285 0.6× 134 1.3× 89 1.1× 95 1.2× 73 0.9× 37 569
Sirijit Suttajit Thailand 16 371 0.8× 155 1.4× 121 1.4× 138 1.7× 58 0.7× 42 682
James M. Eudicone United States 19 643 1.4× 116 1.1× 87 1.0× 227 2.8× 62 0.8× 69 958

Countries citing papers authored by Cedric O’Gorman

Since Specialization
Citations

This map shows the geographic impact of Cedric O’Gorman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cedric O’Gorman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cedric O’Gorman more than expected).

Fields of papers citing papers by Cedric O’Gorman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cedric O’Gorman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cedric O’Gorman. The network helps show where Cedric O’Gorman may publish in the future.

Co-authorship network of co-authors of Cedric O’Gorman

This figure shows the co-authorship network connecting the top 25 collaborators of Cedric O’Gorman. A scholar is included among the top collaborators of Cedric O’Gorman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cedric O’Gorman. Cedric O’Gorman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fava, Maurizio, Stephen M. Stahl, Sara De Martin, et al.. (2023). Esmethadone-HCl (REL-1017): a promising rapid antidepressant. European Archives of Psychiatry and Clinical Neuroscience. 273(7). 1463–1476. 21 indexed citations
2.
O’Gorman, Cedric, et al.. (2020). P.327 Efficacy and safety of AXS-05, an oral, NMDA receptor antagonist with multimodal activity in major depressive disorder. European Neuropsychopharmacology. 40. S190–S190. 3 indexed citations
3.
O’Gorman, Cedric, et al.. (2020). 0739 Efficacy and Safety of AXS-12 in the Treatment of Narcolepsy: Results from a Phase 2, Double-Blind, Placebo-Controlled, Crossover Trial. SLEEP. 43(Supplement_1). A281–A281. 2 indexed citations
4.
O’Gorman, Cedric, et al.. (2019). AXS-05 (Dextromethorphan/Bupropion): psychopharmacology and the potential for therapeutic application in the treatment of neuropsychiatric symptoms. European Neuropsychopharmacology. 29. S458–S458. 2 indexed citations
5.
6.
O’Gorman, Cedric, et al.. (2019). 0058 Scientific Rationale and Clinical Development of AXS-12 for Narcolepsy.. SLEEP. 42(Supplement_1). A24–A25. 2 indexed citations
7.
O’Gorman, Cedric, et al.. (2018). P2‐033: AXS‐05 (DEXTROMETHORPHAN/BUPROPION): AN INNOVATIVE TREATMENT IN CLINICAL DEVELOPMENT FOR AGITATION ASSOCIATED WITH ALZHEIMER'S DISEASE. Alzheimer s & Dementia. 14(7S_Part_12). 1 indexed citations
8.
Blanchard, Jack J., Henry A. Nasrallah, Philip D. Harvey, et al.. (2017). Examining the reliability and validity of the Clinical Assessment Interview for Negative Symptoms within the Management of Schizophrenia in Clinical Practice (MOSAIC) multisite national study. Schizophrenia Research. 185. 137–143. 29 indexed citations
9.
Nasrallah, Henry A., Philip D. Harvey, Daniel E. Casey, et al.. (2015). The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry: A focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization. Schizophrenia Research. 166(1-3). 69–79. 19 indexed citations
10.
Strassnig, Martin, Tenko Raykov, Cedric O’Gorman, et al.. (2015). Determinants of different aspects of everyday outcome in schizophrenia: The roles of negative symptoms, cognition, and functional capacity. Schizophrenia Research. 165(1). 76–82. 141 indexed citations
11.
Schooler, Nina R., Robert W. Buchanan, Thomas Laughren, et al.. (2015). Defining therapeutic benefit for people with schizophrenia: Focus on negative symptoms. Schizophrenia Research. 162(1-3). 169–174. 27 indexed citations
12.
Eisenberg, D., et al.. (2013). Treatment and Healthcare Utilization Among Commercially Insured Patients With Major Depressive Disorder. The American Journal of Managed Care. 5. 1 indexed citations
13.
Pae, Chi‐Un, Prakash S. Masand, Francine S. Mandel, & Cedric O’Gorman. (2012). Achieving and Sustaining Remission in Bipolar I Disorder with Ziprasidone. Clinical Drug Investigation. 32(11). 747–754. 4 indexed citations
14.
Camm, A. John, Onur N. Karayal, Herbert Y. Meltzer, et al.. (2012). Ziprasidone and the Corrected QT Interval. CNS Drugs. 26(4). 351–365. 28 indexed citations
15.
Bowden, Charles L., Onur N. Karayal, Jeffrey H. Schwartz, Balarama Gundapaneni, & Cedric O’Gorman. (2012). Characterizing relapse prevention in bipolar disorder with adjunctive ziprasidone: Clinical and methodological implications. Journal of Affective Disorders. 144(1-2). 171–175. 3 indexed citations
16.
17.
Miceli, Jeffrey, et al.. (2010). Effects of Oral Ziprasidone and Oral Haloperidol on QTc Interval in Patients with Schizophrenia or Schizoaffective Disorder. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 30(2). 127–135. 29 indexed citations
18.
Correll, Christoph U., Benjamin G. Druss, Ilise Lombardo, et al.. (2010). Findings of a U.S. National Cardiometabolic Screening Program Among 10,084 Psychiatric Outpatients. Psychiatric Services. 61(9). 892–898. 87 indexed citations
19.
Masand, Prakash S., Cedric O’Gorman, & Francine S. Mandel. (2010). Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: Analyses of ziprasidone clinical study data. Schizophrenia Research. 126(1-3). 174–183. 16 indexed citations
20.
O’Gorman, Cedric, et al.. (2006). An evaluation of Medline published paediatric audits from 1966 to 1999. Archives of Disease in Childhood. 92(4). 309–311.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luke Vano Breakdown of academic impact, for papers by Ataru Inagaki Breakdown of academic impact, for papers by Margarida García-García Breakdown of academic impact, for papers by Pilar Sierra Breakdown of academic impact, for papers by Gabriella Rapini Breakdown of academic impact, for papers by Anne Emilie Stürup Breakdown of academic impact, for papers by Alexander Brunnauer Breakdown of academic impact, for papers by Jerónimo Sáiz Ruiz Breakdown of academic impact, for papers by Sirijit Suttajit Breakdown of academic impact, for papers by James M. Eudicone
Rankless by CCL
2026